Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics
- PMID: 24889915
- DOI: 10.1016/j.ejca.2014.04.014
Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics
Abstract
Most anticancer drugs are characterised by a steep dose-response relationship and narrow therapeutic window. Inter-individual pharmacokinetic (PK) variability is often substantial. The most relevant PK parameter for cytotoxic drugs is the area under the plasma concentration versus time curve (AUC). Thus it is somewhat surprising that therapeutic drug monitoring (TDM) is still uncommon for the majority of agents. Goals of the review were to assess the rationale for more widely used TDM of cytotoxics in oncology. There are several reasons why TDM has never been fully implemented into daily oncology practice. These include difficulties in establishing appropriate concentration target ranges, common use of combination chemotherapies for many tumour types, analytical challenges with prodrugs, intracellular compounds, the paucity of published data from pharmacological trials and 'Day1 = Day21' administration schedules. There are some specific situations for which these limitations are overcome, including high dose methotrexate, 5-fluorouracil infusion, mitotane and some high dose chemotherapy regimens. TDM in paediatric oncology represents an important challenge. Established TDM approaches includes the widely used anticancer agents carboplatin, busulfan and methotrexate, with 13-cis-retinoic acid also recently of interest. Considerable effort should be made to better define concentration-effect relationships and to utilise tools such as population PK/PD models and comparative randomised trials of classic dosing versus pharmacokinetically guided adaptive dosing. There is an important heterogeneity among clinical practices and a strong need to promote TDM guidelines among the oncological community.
Keywords: 5-Fluorouracil; Busulfan; Chemotherapy; Cytotoxics; Methotrexate; Mitotane; Oncology; Paediatric oncology; Pharmacokinetics; Therapeutic drug monitoring.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
Therapeutic drug monitoring in cancer--are we missing a trick?Eur J Cancer. 2014 Aug;50(12):2005-9. doi: 10.1016/j.ejca.2014.04.013. Epub 2014 May 27. Eur J Cancer. 2014. PMID: 24878063
-
Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.Eur J Cancer. 2014 Aug;50(12):2020-36. doi: 10.1016/j.ejca.2014.04.015. Epub 2014 Jun 10. Eur J Cancer. 2014. PMID: 24928190 Review.
-
Target concentration intervention in oncology: where are we at?Ther Drug Monit. 2012 Jun;34(3):257-65. doi: 10.1097/FTD.0b013e3182557342. Ther Drug Monit. 2012. PMID: 22585183 Review.
-
Therapeutic drug monitoring of cancer chemotherapy.J Oncol Pharm Pract. 2007 Dec;13(4):207-21. doi: 10.1177/1078155207081133. J Oncol Pharm Pract. 2007. PMID: 18045780 Review.
-
Therapeutic drug monitoring in cancer chemotherapy.Bioanalysis. 2010 May;2(5):863-79. doi: 10.4155/bio.10.48. Bioanalysis. 2010. PMID: 21083218 Review.
Cited by
-
Ferroptosis-based molecular prognostic model for adrenocortical carcinoma based on least absolute shrinkage and selection operator regression.J Clin Lab Anal. 2022 Jun;36(6):e24465. doi: 10.1002/jcla.24465. Epub 2022 May 2. J Clin Lab Anal. 2022. PMID: 35500219 Free PMC article.
-
External Evaluation of Population Pharmacokinetic Models of Busulfan in Chinese Adult Hematopoietic Stem Cell Transplantation Recipients.Front Pharmacol. 2022 Jul 7;13:835037. doi: 10.3389/fphar.2022.835037. eCollection 2022. Front Pharmacol. 2022. PMID: 35873594 Free PMC article.
-
Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients.Cancer Chemother Pharmacol. 2021 Feb;87(2):229-239. doi: 10.1007/s00280-020-04208-8. Epub 2021 Jan 2. Cancer Chemother Pharmacol. 2021. PMID: 33386926
-
From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology.Drugs. 2025 Apr;85(4):487-503. doi: 10.1007/s40265-025-02152-6. Epub 2025 Feb 12. Drugs. 2025. PMID: 39939511 Free PMC article. Review.
-
Feedback Control over Plasma Drug Concentrations Achieves Rapid and Accurate Control over Solid-Tissue Drug Concentrations.ACS Pharmacol Transl Sci. 2025 Apr 11;8(5):1416-1423. doi: 10.1021/acsptsci.5c00142. eCollection 2025 May 9. ACS Pharmacol Transl Sci. 2025. PMID: 40370982
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources